Biotech Archives - Page 724 of 795

3 minute read

Codiak BioSciences Announces Program Reprioritization And Pausing Of Plans To Initiate Phase 2 Trials Of exoSTING And exoIL-12; Co. Also Announces Corporate Restructuring Including 37% Workforce Reduction

August 30, 9:14 AM

– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma

CDAK

3 minute read

FDA
News

OKYO Pharma Plans Q4 2022 IND Filing Of OK-101 To Treat Dry Eye Disease With Subsequent Phase 2 Initiation

By Benzinga Newsdesk

August 30, 9:06 AM

OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential. IND

OKYO

1 minute read

Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold

By Vandana Singh

August 30, 8:52 AM

The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.

CRIS

3 minute read

Jaguar Health Announces Submission Of IND Application To FDA For Drug Candidate For The Relief Of Diarrhea From Cholera

By Benzinga Newsdesk

August 30, 8:36 AM

Jaguar is concentrating financial and management resources on two near-term late-stage clinical events

JAGX

1 minute read

Jounce Therapeutics Reports Results From Phase 2 Randomized SELECT Trial Testing 2 Different Doses Of Vopratelimab In TISvopra Biomarker-Selected Patients; Co. Reports Study Did Not Meet Its Primary Endpoint

By Benzinga Newsdesk

August 30, 8:14 AM

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in improved mean tumor

JNCE

2 minute read

Cybin Inc. Announces First Participants Dosed In Its Phase 1/2a Trial Of CYB003 For The Treatment Of Major Depressive Disorder

By Benzinga Newsdesk

August 30, 8:10 AM

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce that the first

CYBN

1 minute read

Arbutus Biopharma Announces Issuance Of US Patent Related To AB-729

By Bill Haddad

August 30, 7:31 AM

Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that

ABUS

1 minute read

Sanofi’s Hemophilia Candidate Goes Under Priority FDA Review

By Vandana Singh

August 30, 6:46 AM

The FDA has accepted for priority review Sanofi SA’s (NASDAQ:SNY) marketing application for efanesoctocog alfa (BIVV001) for hemophilia A, a rare…

BIOVF

2 minute read

Pfizer-BioNTech, Moderna Set To Get FDA Nod For Omicron Booster Shots As Early As Wednesday: Report

By Shanthi Rexaline

August 30, 2:34 AM

Booster shots for Omicron variants of the novel coronavirus could officially be made available in the U.S. just after Labor Day, Politico reported on Monday.

BNTX